Solventum Corporation (NYSE:SOLV) Given Consensus Recommendation of “Hold” by Analysts

Shares of Solventum Corporation (NYSE:SOLV) have received an average recommendation of “Hold” from the thirteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $91.6364.

A number of analysts have recently commented on the stock. Piper Sandler lifted their price target on shares of Solventum from $92.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Wells Fargo & Company lowered their price objective on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 6th. KeyCorp raised their target price on shares of Solventum from $93.00 to $102.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Mizuho set a $113.00 target price on Solventum in a report on Thursday, August 6th. Finally, Wall Street Zen raised Solventum from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th.

Hedge Funds Weigh In On Solventum

Institutional investors have recently made changes to their positions in the business. CrossGen Wealth LLC bought a new stake in Solventum during the fourth quarter valued at approximately $25,000. Measured Wealth Private Client Group LLC purchased a new stake in Solventum during the third quarter valued at approximately $25,000. Clearstead Trust LLC raised its position in Solventum by 61.0% in the first quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock worth $26,000 after acquiring an additional 150 shares during the period. JNBA Financial Advisors raised its position in Solventum by 205.4% in the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after acquiring an additional 228 shares during the period. Finally, CYBER HORNET ETFs LLC purchased a new position in shares of Solventum during the 2nd quarter worth $28,000.

Solventum Price Performance

Shares of SOLV opened at $85.52 on Friday. Solventum has a twelve month low of $62.38 and a twelve month high of $90.00. The company has a market capitalization of $14.56 billion, a P/E ratio of 10.45, a price-to-earnings-growth ratio of 1.08 and a beta of 0.60. The firm has a 50 day moving average of $79.88 and a 200 day moving average of $74.52. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The business had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.15 billion. During the same period in the prior year, the firm posted $1.69 EPS. The firm’s quarterly revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, equities research analysts anticipate that Solventum will post 7.24 earnings per share for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.